Positive News Coverage Somewhat Unlikely to Affect Moleculin Biotech (MBRX) Stock Price

News stories about Moleculin Biotech (NASDAQ:MBRX) have trended positive recently, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Moleculin Biotech earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.7536337068095 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Separately, ValuEngine raised shares of Moleculin Biotech from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.

Shares of Moleculin Biotech (NASDAQ MBRX) traded down $0.02 during midday trading on Friday, hitting $1.69. 122,500 shares of the stock were exchanged, compared to its average volume of 1,276,156. Moleculin Biotech has a twelve month low of $0.71 and a twelve month high of $3.75.

Moleculin Biotech (NASDAQ:MBRX) last issued its quarterly earnings data on Tuesday, November 14th. The company reported ($0.14) EPS for the quarter.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.com-unik.info/2017/12/15/positive-news-coverage-somewhat-unlikely-to-affect-moleculin-biotech-mbrx-stock-price.html.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML).

Insider Buying and Selling by Quarter for Moleculin Biotech (NASDAQ:MBRX)

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit